AstraZeneca
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · United Kingdom · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Biomedical Campus 1 Francis Crick Cambri...Phone Number
+442037495000Website
www.astrazeneca.comRevenue
$58.7 BillionStock Symbol
AZNIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
4
4
4
3
2
About AstraZeneca
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.Explore more
AstraZeneca Org Chart
RL
Business Controller
SC
Area Financial Controller (Asia)
TA
Controller
IK
African Cluster Senior Finance Controller
ZC
Country Controller
TS
Financial Controller
SS
Reporting Analyst
KP
Zealand Financial Controller (Australia)
KV
Assistant Depot Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AstraZeneca your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if AstraZeneca is spiking on competitors!
Funding: Get notified immidiatlly once AstraZeneca has new funding data
AstraZeneca, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at AstraZeneca
Earning: See what the market has to say on AstraZeneca recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if AstraZeneca had a recent Job posting/layoffs
Check if AstraZeneca has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when AstraZeneca launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to AstraZeneca
Compare insights from companies similar to AstraZeneca, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AstraZeneca
$58.7B
10K+
Public
$4.7B
1999
RH
Richard HasselbuschVice President and Chief Financial Officer, Global Operations and Information Technology
$54.2B
10K+
Public
-
1994
AA
Alberto AbrilGlobal Head, Medical Affairs Research & Development Information Solutions
$44B
10K+
Public
-
2000
YG
Yvette GainesManager, Sample and Promotional Operations Chief of Staff, Enterprise Operations
Company Profile Activity
Activity Insights
AstraZeneca is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AstraZeneca is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AstraZeneca.
AstraZeneca financials insights
Gather financial insights about AstraZeneca, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$1B
2021
Other Financing Round
$168M
2024
Unspecified
$3.5B
AstraZeneca Tech Stack
A closer look at the technologies used by AstraZeneca
Most Recent Scoops
Earnings
AstraZeneca has reported Saphnelo revenue growth of 24% to $209 million in H1, driven by share gains in the intravenous segment for systemic lupus erythematosus patients, with the new subcutaneous formulation now available in the US and select European markets.
Earnings, Pharmaceuticals, Finance
Project
AstraZeneca is advancing its oral PCSK9 inhibitor laroprovstat toward a phase III readout in H1 2027 and is advancing the first fixed-dose combination of laroprovstat with rosuvastatin into phase III for dyslipidemia.
Pharmaceuticals
Earnings
AstraZeneca has reported total revenue growth of 6% in H1, with core EPS increasing 11%. Excluding the impact of Farxiga and BRILINTA, which are affected by generics, total revenue grew 11%.
Earnings, Finance
Earnings
AstraZeneca has reiterated its $80 billion revenue ambition for 2030, describing the target as a risk-adjusted forecast based on the strength of a broad and diversified portfolio, noting that outperformance across all programs could result in revenues exceeding that figure.
Earnings, Forecasting, Finance, Risk
Project
Clinical Operations
AstraZeneca News & Media
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed […]Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors
The AstraZeneca–BMS merger story explained: what was reported, what was denied, what regulators would scrutinize, and what it means for pharma.Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a […]Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AstraZeneca
Sign Up For FreeTo access detailed company insights
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.... Read More
